Shattuck Labs Will Present Data at UEG Week 2026
The company plans to unveil research on SL-846 and TL1A immune complexes during the October congress in Barcelona.
Updated on Oct. 13, 2026 in Biotech
Shattuck Labs has scheduled two research presentations for the upcoming United European Gastroenterology Week, which takes place in Barcelona, Spain, between October 17 and October 20, 2026. The company will showcase experimental developments regarding its SL-846 compound and TL1A immune complex pathways.
Why it matters
These presentations mark a public disclosure of progress for Shattuck Labs as it iterates on its platform for modulating immune responses. The findings offer a window into the current state of its internal development pipeline for gastrointestinal and immunological therapies.
Shattuck Labs is set to present two distinct posters, covering the development of SL-846 and research on how soluble TL1A immune complexes induce the de novo production of TL1A. Full technical characterization remains pending until the conclusion of the event.
The players
Shattuck Labs
A biotechnology company based in Austin, Texas and Durham, North Carolina that focuses on the development of dual-sided fusion proteins for immune system modulation.
Mahmud Hussain
A researcher tasked with leading the presentation regarding the characterization and development of the compound SL-846.
Suresh de Silva
A researcher presenting findings on the biological mechanism of TL1A immune complexes and their role in cytokine production.
The details
The research on SL-846 will be delivered during a moderated poster session, a format where presenters discuss their findings with assigned session experts. The second presentation, focusing on TL1A immune complexes—clusters of antibodies bound to the cytokine TL1A—examines their role in stimulating the production of additional TL1A, a pro-inflammatory protein. These insights detail the mechanistic signaling pathways Shattuck Labs is currently investigating to influence immune system regulation.
Timeline
United European Gastroenterology Week 2026 runs from October 17 to October 20, 2026.
The moderated poster presentation on SL-846 is scheduled for October 19, 2026.
The Tech Race
These presentations occur at the United European Gastroenterology Week, a primary venue for evaluating new data in gastrointestinal health. Shattuck Labs is using this platform to advance its positioning against ongoing immunological research programs.
This disclosure provides transparency into the research pipeline for those tracking Shattuck Labs' therapeutic progress. Access to the full poster data will be open to the public via the company's investor relations portal immediately following the event.
The takeaway
These presentations represent a milestone in the disclosure of Shattuck Labs' experimental immune modulation platforms. Watch for the public release of the posters after October 20, 2026, to analyze the specific performance data demonstrated at the congress.
What happens next
The posters and associated research findings will be available on the Shattuck Labs company website following the conclusion of the congress on October 20, 2026.
Further reading
Explore deeper insights into current therapeutic developments by visiting our Biotech section.
More information
View full documentation and future updates on the Company investor relations website.
